These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 31584140)

  • 21. Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers.
    Toledo FGS; Martin WF; Morrow L; Beysen C; Bajorunas D; Jiang Y; Silverman BL; McDonnell D; Namchuk MN; Newcomer JW; Graham C
    Neuropsychopharmacology; 2022 Feb; 47(3):696-703. PubMed ID: 34887529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension.
    Kahn RS; Silverman BL; DiPetrillo L; Graham C; Jiang Y; Yin J; Simmons A; Bhupathi V; Yu B; Yagoda S; Hopkinson C; McDonnell D
    Schizophr Res; 2021 Jun; 232():45-53. PubMed ID: 34015555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.
    Sun L; Mills R; Sadler BM; Rege B
    J Clin Pharmacol; 2021 Nov; 61(11):1430-1441. PubMed ID: 34018607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review.
    Laguado SA; Saklad SR
    Ment Health Clin; 2022 Aug; 12(4):254-262. PubMed ID: 36071739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study.
    Kahn RS; Kane JM; Correll CU; Arevalo C; Simmons A; Graham C; Yagoda S; Hu B; McDonnell D
    J Clin Psychiatry; 2023 Mar; 84(3):. PubMed ID: 36946605
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.
    Correll CU; Newcomer JW; Silverman B; DiPetrillo L; Graham C; Jiang Y; Du Y; Simmons A; Hopkinson C; McDonnell D; Kahn RS
    Am J Psychiatry; 2020 Dec; 177(12):1168-1178. PubMed ID: 32791894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates.
    Cunningham JI; Eyerman DJ; Todtenkopf MS; Dean RL; Deaver DR; Sanchez C; Namchuk M
    J Psychopharmacol; 2019 Oct; 33(10):1303-1316. PubMed ID: 31294646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
    Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW
    Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo Characterization of the Opioid Receptor-Binding Profiles of Samidorphan and Naltrexone in Rats: Comparisons at Clinically Relevant Concentrations.
    Tan LA; Gajipara N; Sun L; Bacolod M; Zhou Y; Namchuk M; Cunningham JI
    Neuropsychiatr Dis Treat; 2022; 18():2497-2506. PubMed ID: 36345421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials.
    Rehan ST; Siddiqui AH; Khan Z; Imran L; Syed AA; Tahir MJ; Jassani Z; Singh M; Asghar MS; Ahmed A
    Ann Med Surg (Lond); 2022 Jul; 79():104115. PubMed ID: 35860157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olanzapine/samidorphan combination consistently mitigates weight gain across various subgroups of patients.
    Meyer JM; Simmons A; Jiang Y; Graham C; Yagoda S; McDonnell D
    CNS Spectr; 2023 Aug; 28(4):478-481. PubMed ID: 36226902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risperidone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder.
    Ravindran A; Silverstone P; Lacroix D; van Schaick E; Vermeulen A; Alexander J
    Clin Pharmacokinet; 2004; 43(11):733-40. PubMed ID: 15301577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The SNAP 101 Double-Blind, Placebo/Active-Controlled, Safety, Pharmacokinetic, and Pharmacodynamic Study of INP105 (Nasal Olanzapine) in Healthy Adults.
    Shrewsbury SB; Hocevar-Trnka J; Satterly KH; Craig KL; Lickliter JD; Hoekman J
    J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32609960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers.
    Turncliff R; DiPetrillo L; Silverman B; Ehrich E
    Clin Ther; 2015 Feb; 37(2):338-48. PubMed ID: 25456560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Valproate or olanzapine add-on to lithium: an 8-week, randomized, open-label study in Italian patients with a manic relapse.
    Maina G; Albert U; Salvi V; Mancini M; Bogetto F
    J Affect Disord; 2007 Apr; 99(1-3):247-51. PubMed ID: 17056122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.
    Correll CU; Stein E; Graham C; DiPetrillo L; Akerman S; Stanford AD; Jiang Y; Yagoda S; McDonnell D; Hopkinson C
    Schizophr Bull; 2023 Mar; 49(2):454-463. PubMed ID: 36305696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.
    Hayes JF; Marston L; Walters K; Geddes JR; King M; Osborn DP
    PLoS Med; 2016 Aug; 13(8):e1002058. PubMed ID: 27483368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Olanzapine/Samidorphan: First Approval.
    Paik J
    Drugs; 2021 Aug; 81(12):1431-1436. PubMed ID: 34304374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.